Stay updated with breaking news from Nasdaq Agle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A number of research firms have changed their ratings and price targets for Aeglea BioTherapeutics (NASDAQ: AGLE): 4/12/2023 – Aeglea BioTherapeutics was downgraded by analysts at Lifesci Capital from an “outperform” rating to a “market perform” rating. 4/12/2023 – Aeglea BioTherapeutics had its “hold” rating reaffirmed by analysts at Jonestrading. 4/12/2023 – Aeglea BioTherapeutics was […]
Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) was downgraded by investment analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued to investors on Wednesday, The Fly reports. AGLE has been the subject of a number of other research reports. HC Wainwright reiterated a “neutral” rating […]
StockNews.com assumed coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) in a research note published on Monday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright reiterated a neutral rating and issued a $1.00 price objective on shares of Aeglea BioTherapeutics in a report on Friday, March […]
StockNews.com initiated coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) in a research note published on Monday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright restated a neutral rating and issued a $1.00 price objective on shares of Aeglea BioTherapeutics in a research note on Friday, […]
StockNews.com began coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) in a research report sent to investors on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright reiterated a neutral rating and set a $1.00 price target on shares of Aeglea BioTherapeutics in a research report on […]